Anti-Human CD56 (NCAM) PE

Grouped product items
Size Price Qty
25 tests
$210.00
100 tests
$425.00

Additional TULY56 Formats

Cat.No. Format Starting From
08641-80 APC $ 210.00
08641-50 FITC $ 185.00
08641-60 PE $ 210.00
Catalog Number : 08641-60

description

The TULY56 monoclonal antibody specifically reacts with human CD56, or Neural Cell Adhesion molecule (NCAM). CD56 is a 140 kDa transmembrane glycoprotein also known as Leu-19 or NKH1. It is expressed on NK and NKT cells and has a role in cellular adhesion. The TULY56 antibody is reported to bind to a different epitope than the CMSSB antibody and does not block its binding.

Additional Information

Clone:
TULY56
Format:
PE
Applications:
FC
Reactivity:
Human
Isotype:
Mouse IgG1, kappa
Research Interest: Innate Immunity
Cell Type: NK and NKT Cells
Application: FC
Clone: TULY56
Preparation:
The product should be stored undiluted at 4°C and should be protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product.
Formulation:
Phosphate-buffered aqueous solution, ≤0.09% Sodium azide, may contain carrier protein/stabilizer, ph7.2.
References:

Walker, W. E., Kurscheid, S., Joshi, S., Lopez, C. A., Goh, G., Choi, M., ... & Zapata, H. (2015). Increased levels of macrophage inflammatory proteins result in resistance to R5-tropic HIV-1 in a subset of elite controllers. Journal of virology89(10), 5502-5514.

Selb, R., Eckl-Dorna, J., Neunkirchner, A., Schmetterer, K., Marth, K., Gamper, J., ... & Niederberger, V. (2017). CD23 surface density on B cells is associated with IgE levels and determines IgE-facilitated allergen uptake, as well as activation of allergen-specific T cells. Journal of Allergy and Clinical Immunology139(1), 290-299.

Kim, N., Jeon, Y. W., Nam, Y. S., Lim, J. Y., Im, K. I., Lee, E. S., & Cho, S. G. (2016). Therapeutic potential of low-dose IL-2 in a chronic GVHD patient by in vivo expansion of regulatory T cells. Cytokine78, 22-26.

© BioGems International, Inc. All rights reserved.